Movantik

Chemical Namenaloxegol
Dosage FormTablet (oral; 12.5mg, 25mg)
Drug ClassReceptor antagonists
SystemDigestion
CompanyAstraZeneca
Approval Year2014

Indication

  • For the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Movantik (naloxegol) Prescribing Information2014AstraZeneca Pharmaceuticals LP, Wilmington, DE